CERO THERAPEUTICS HOLDINGS, INC.

CERO

Explore Our Financial Data > Companies > CERO THERAPEUTICS HOLDINGS, INC.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
CERO
CIK0001870404
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080
Website N/A
Phone650-407-2376
CEOChristopher B. Ehrlich
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$0.00
Pre-Tax Income$-7.23 million
Net Income$-7.29 million
Net Income to Common$-7.29 million
EPS$-1,248.64
View All
Balance Sheet
CashN/A
Assets$7.99 million
Liabilities$8.32 million
Common Equity$-2.76 million
Liabilities & Equity$7.99 million
View All
Cash Flow Statement
Net Income$-7.29 million
Cash From Operating Activities$-5.79 million
Cash From Investing Activities$0.00
Cash From Financing Activities$571,678.00
Change in Cash$-5.22 million
View All
Calculations
NOPAT$-5.37 million
EBITDA$-6.25 million
Price to EarningsN/A
Price to BookN/A
ROE-580.30%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial’s Dose Escalation Safety Committee, preliminary resul

Article Link

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index dropping 1.7% and

Article Link

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 i

Article Link

Cero Therapeutics announces 1-for-20 reverse stock split

CERo Therapeutics (CERO) announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company’s common stock, par value $0.0001 per share. The reverse stock split will take effect at 12:01 a.m. Eastern Time on June 13, 2025, and the Company’s Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on June 13, 2025. The CUSIP number of 71902K402 will be assigned to the Company’s Common Stock

Article Link

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The reverse stock split will t

Article Link